JWC logo and link to home page

The professional's guide to product selection

Dupixent

Sanofi UK

DESCRIPTION

Dupilumab is a recombinant human IgG4 monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling. Dupilumab inhibits IL-4 signaling via the Type I receptor (IL-4Rα/γc), and both IL-4 and IL-13 signaling through the Type II receptor (IL-4Rα/IL-13Rα). IL-4 and IL-13 are key type 2 (including Th2) cytokines involved in atopic dermatitis.

INDICATIONS

Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.

PREPARATIONS AVAILABLE

Injection

SIZES AVAILABLE

300mg/2ml (pre-filled syringe)

PRICE

£1264.89 (2 filled syringes)